Your browser doesn't support javascript.
loading
Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications.
Adelaiye, Remi; Ciamporcero, Eric; Miles, Kiersten Marie; Sotomayor, Paula; Bard, Jonathan; Tsompana, Maria; Conroy, Dylan; Shen, Li; Ramakrishnan, Swathi; Ku, Sheng-Yu; Orillion, Ashley; Prey, Joshua; Fetterly, Gerald; Buck, Michael; Chintala, Sreenivasulu; Bjarnason, Georg A; Pili, Roberto.
Afiliação
  • Adelaiye R; Genitourinary Program, Roswell Park Cancer Institute, Buffalo, New York. Department of Cancer Pathology and Prevention, Roswell Park Cancer Institute Division, University at Buffalo, Buffalo, New York.
  • Ciamporcero E; Genitourinary Program, Roswell Park Cancer Institute, Buffalo, New York. Department of Medicine and Experimental Oncology, University of Turin, Turin, Italy.
  • Miles KM; Genitourinary Program, Roswell Park Cancer Institute, Buffalo, New York.
  • Sotomayor P; Genitourinary Program, Roswell Park Cancer Institute, Buffalo, New York. Department of Molecular and Cellular Biology, Roswell Park Cancer Institute, Buffalo, New York.
  • Bard J; Center of Excellence in Bioinformatics and Life Sciences, University at Buffalo, Buffalo, New York.
  • Tsompana M; Center of Excellence in Bioinformatics and Life Sciences, University at Buffalo, Buffalo, New York.
  • Conroy D; Genitourinary Program, Roswell Park Cancer Institute, Buffalo, New York.
  • Shen L; Genitourinary Program, Roswell Park Cancer Institute, Buffalo, New York.
  • Ramakrishnan S; Genitourinary Program, Roswell Park Cancer Institute, Buffalo, New York. Department of Cancer Pathology and Prevention, Roswell Park Cancer Institute Division, University at Buffalo, Buffalo, New York.
  • Ku SY; Genitourinary Program, Roswell Park Cancer Institute, Buffalo, New York. Department of Cancer Pathology and Prevention, Roswell Park Cancer Institute Division, University at Buffalo, Buffalo, New York.
  • Orillion A; Department of Molecular and Cellular Biology, Roswell Park Cancer Institute, Buffalo, New York.
  • Prey J; Pharmacokinetics and Pharmacodynamics Core Facility, Roswell Park Cancer Institute, Buffalo, New York.
  • Fetterly G; Pharmacokinetics and Pharmacodynamics Core Facility, Roswell Park Cancer Institute, Buffalo, New York.
  • Buck M; Center of Excellence in Bioinformatics and Life Sciences, University at Buffalo, Buffalo, New York.
  • Chintala S; Genitourinary Program, Roswell Park Cancer Institute, Buffalo, New York. Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York.
  • Bjarnason GA; Sunnybrook Odette Cancer Center, University of Toronto, Toronto, Ontario, Canada. Roberto.Pili@RoswellPark.org georg.bjarnason@utoronto.ca.
  • Pili R; Genitourinary Program, Roswell Park Cancer Institute, Buffalo, New York. Department of Cancer Pathology and Prevention, Roswell Park Cancer Institute Division, University at Buffalo, Buffalo, New York. Roberto.Pili@RoswellPark.org georg.bjarnason@utoronto.ca.
Mol Cancer Ther ; 14(2): 513-22, 2015 Feb.
Article em En | MEDLINE | ID: mdl-25519701
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirróis / Carcinoma de Células Renais / Resistencia a Medicamentos Antineoplásicos / Epigênese Genética / Indóis / Neoplasias Renais Tipo de estudo: Risk_factors_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirróis / Carcinoma de Células Renais / Resistencia a Medicamentos Antineoplásicos / Epigênese Genética / Indóis / Neoplasias Renais Tipo de estudo: Risk_factors_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article